TI
ITOS

Trexquant Investment’s iTeos Therapeutics ITOS Stock Holding History

Trexquant Investment’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-188,500
Closed -$1.13M – 1710
2025
Q1 		$1.13M Buy
188,500
+8,534
+5% +$62.7K 0.01% 1049
2024
Q4 		$1.38M Buy
179,966
+130,960
+267% +$1.13M 0.02% 1000
2024
Q3 		$500K Buy
+49,006
New +$748K 0.01% 1251
2024
Q2 		– Sell
-25,886
Closed -$353K – 1683
2024
Q1 		$353K Sell
25,886
-35,772
-58% -$390K 0.01% 1246
2023
Q4 		$675K Buy
61,658
+28,109
+84% +$279K 0.02% 965
2023
Q3 		$367K Buy
33,549
+3,268
+11% +$41.8K 0.01% 1142
2023
Q2 		$401K Buy
30,281
+16,348
+117% +$233K 0.01% 1089
2023
Q1 		$190K Buy
+13,933
New +$250K 0.01% 1329
2022
Q3 		– Sell
-24,738
Closed -$510K – 1607
2022
Q2 		$510K Buy
24,738
+9,914
+67% +$235K 0.02% 816
2022
Q1 		$477K Buy
+14,824
New +$539K 0.02% 786
2021
Q3 		– Sell
-25,778
Closed -$661K – 1312
2021
Q2 		$661K Buy
+25,778
New +$614K 0.06% 400

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Trexquant Investment's ITOS Position: Q2 2025 in Review

Trexquant Investment sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 188,500 shares — an estimated $1.13M sold.

Trexquant Investment first reported a position in ITOS in Q2 2021 and held it in 11 quarters. The position peaked at $1.38M in Q4 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Trexquant Investment reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Trexquant Investment sold 188,500 iTeos Therapeutics shares in Q2 2025, an estimated $1.13M.
  • Trexquant Investment first reported a position in iTeos Therapeutics in Q2 2021 and held it in 11 quarters.
  • Trexquant Investment's iTeos Therapeutics position peaked at $1.38M in Q4 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Trexquant Investment's 13F filing for Q2 2025, filed 12 Aug 2025.